Results 91 to 100 of about 3,103 (173)

The Current and Future Impact of WHO Guidance on Global HIV Pre-Exposure Prophylaxis Programs: A Narrative Review. [PDF]

Infect Drug Resist
Mishriky F, Chan PA.
europepmc   +1 more source

Cabotegravir pharmacokinetics in Asians with and without HIV

Int. Journal of Clinical Pharmacology and Therapeutics
Han, Kelong, Abulfathi, Ahmed A., Mehta, Rashmi S., Nand, Romina A., Marzinke, Mark A., Landovitz, Raphael J., D’Amico, Ronald D., Rinehart, Alex R., Spreen, William R., Ford, Susan L.   +9 more
openaire   +2 more sources

Lenacapavir as pre-exposure prophylaxis for HIV prevention. [PDF]

Cochrane Database Syst Rev
Ebrahim S, Gloeck N, Adam Z, Tatz G, Nel J, Sinxadi PZ, Dawood H, Kredo T, Cohen K.   +8 more
europepmc   +1 more source

Use of DNA profiling to resolve HIV status in a person using injectable cabotegravir for HIV pre-exposure prophylaxis. [PDF]

J Clin Pathol
Fogel JM, Salih MA, Haddaway K, Marzinke MA, Marshall C, Wang Z, Cummings V, Piwowar-Manning E, Rooney JF, McCauley M, Grinsztejn B, Landovitz RJ, Eshleman SH.   +12 more
europepmc   +1 more source

Dual Long-Acting Cabotegravir/Rilpivirine Plus Lenacapavir in Integrase Strand Transfer Inhibitor Resistance: A Case Report and Review of the Literature. [PDF]

Open Forum Infect Dis
Seo L, Reilly-Evans B, Garland J.
europepmc   +1 more source

The effect of long-acting cabotegravir and rilpivirine treatment on drug resistance in South Africa: a modelling study. [PDF]

Lancet Glob Health
Han N, Loosli T, Anderegg N, Hauser A, Josi J, Davies MA, Johnson LF, Lessells R, Günthard HF, Egger M, Kouyos RD.   +10 more
europepmc   +1 more source

Letter to the editor: Addressing the blind spot of self-reported adherence in the era of long-acting PrEP

Eurosurveillance
Francesca Venturini
doaj   +1 more source

Policy Recommendations to Support Equitable Access to Long-Acting Injectables for HIV Prevention and Treatment: A Policy Paper of the Infectious Diseases Society of America and the HIV Medicine Association. [PDF]

Clin Infect Dis
Marcus JL, Weddle A, Kelley CF, Agwu A, Montalvo S, Sherman E, Vijayan T, Gutierrez J, Hickey MD, Dilworth SE, Krakower D, Davis TL, Collins LF, McNulty MC, Colasanti JA, Christopoulos KA.   +15 more
europepmc   +1 more source

Dynamic choice HIV prevention with long-acting injectable cabotegravir pre-exposure prophylaxis in east, central, southern, and west Africa: a cost-effectiveness modelling analysis. [PDF]

Lancet HIV
Phillips AN, Hickey MD, Shade SB, Kabami J, Ayieko J, Revill P, Kakande E, Balzer LB, Sutter N, Bansi-Matharu L, Smith J, Chamie G, Havlir DV, Kamya MR, Petersen M.   +14 more
europepmc   +1 more source